Trevi Therapeutics (NASDAQ:TRVI) posted its quarterly earnings results on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.07, Fidelity Earnings reports.
Trevi Therapeutics stock opened at $4.20 on Friday. The business has a 50-day simple moving average of $3.86. Trevi Therapeutics has a 1 year low of $2.65 and a 1 year high of $10.62.
A number of research analysts have recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and issued a $18.00 price target on shares of Trevi Therapeutics in a research report on Friday. Zacks Investment Research upgraded shares of Trevi Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, October 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $16.75.
About Trevi Therapeutics
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.
Further Reading: What is the Bid-Ask Spread?
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.